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Introduction
Non-epithelial malignant breast tumors compose a rare
and heterogenic group of malignancies. They represent
less than 1% of primary mammary malignant tumors [1-
3]. Breast sarcomas and malignant cystosarcoma phyllo-
des tumors are of special interest. Many aspects of their
clinical course are similar [3]. Clinical similarities and
the rarity of these clinical entities are the main reasons
due to which many authors studied these malignancies
together [3-7]. Moreover, some authors rate malignant
cystosarcoma phyllodes tumors among breast sarcomas
[4-7].
Surgical resection is the primary treatment of such
malignancies, however, further details concerning best
treatment options remain unknown [8].
First, the extent of the surgical procedure is contro-
versial. Some authors have claimed that mastectomy
should be a standard procedure in such patients [2, 4, 9-
11] having found that the incidence of relapses was lower
among patients treated with mastectomy than among
those treated with limited surgery. Other authors have
recommended wide local excision as a good alternative
for mastectomy, reporting no differences in disease free
and overall survival between the compared treatment
groups [3, 5, 6, 8, 12]. It is difficult to resolve this contro-
versy as no prospective study has been conducted on the
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I n t r o d u c t i o n.  The aim of the study was to perform a retrospective assessment of the outcome of patients with non-epithelial
malignant breast tumors, treated exclusively by surgery.
M a t e r i a l  a n d  m e t h o d s.  We collected the survival data of 29 women with breast sarcoma or malignant cystosarcoma
phyllodes, treated surgically between 1977 and 2001. The median size of the tumor was 10 cm (range: 3-30 cm).
R e s u l t s.  Recurrence of the disease was observed in 11 patients (38%), and 8 patients died during follow-up (28%). The
probability of disease-free survival was 0.55 at 5 years and 0.44 at 10 years. The overall survival probability was 0.69 at 5 years
and 0.61 at 10 years. A majority of the patients with recurrence (10/11; 91%) and all patients who had died had tumors larger
than 5 cm.
C o n c l u s i o n.  The probability of disease relapse in patients with non-epithelial malignant breast tumors treated surgically
is high in patients with tumors larger than 5 cm.
Nienab∏onkowe z∏oÊliwe nowotwory piersi: retrospektywne badanie obejmujàce 29 chorych 
leczonych tylko chirurgicznie
W p r o w a d z e n i e.  Celem badania by∏a retrospektywna ocena wyników leczenia chirurgicznego chorych na nienab∏onkowe,
z∏oÊliwe nowotwory piersi.
M a t e r i a ∏  i m e t o d y.  Dane na temat prze˝yç wszystkich 29 kobiet chorych na mi´saki piersi i z∏oÊliwe guzy liÊciaste,
leczonych w Klinice w latach 1977-2001, uzyskano z historii chorób. Mediana Êrednicy guza wynosi∏a 10 cm (zakres: 3-30 cm).
W y n i k i.  W okresie obserwacji nawrót choroby stwierdzono u 11 chorych (38%), a 8 chorych zmar∏o (28%).
Prawdopodobieƒstwo prze˝ycia 5 lat bez choroby wynosi∏o 0,55, a prze˝ycia 10 lat wynosi∏o 0,44. Ca∏kowite
prawdopodobieƒstwo prze˝ycia wynosi∏o 0,69 po up∏ywie 5 lat i 0,61 po up∏ywie 10 lat. U wi´kszoÊci chorych, u których dosz∏o
do nawrotu choroby (10/11; 91%), oraz u wszystkich chorych, które zmar∏y, guz pierwotny by∏ wi´kszy ni˝ 5 cm.
W n i o s e k.  Prawdopodobieƒstwo nawrotu choroby u leczonych chirurgicznie chorych na nienab∏onkowe z∏oÊliwe nowotwory
piersi, których Êrednica jest wi´ksza od 5 cm, jest du˝e.
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influence of the extent of surgical treatment on patient
survival. All conclusions base on retrospective studies
results.
Second, the role of adjuvant therapy has not been
established [5, 13, 14]. It has been stated that adjuvant
radiotherapy is not likely to be beneficial [9, 13, 15],
however has also been advised cautiously to consider such
a treatment option [13, 14]. Other authors have reported
the excellent efficacy of postoperative radiotherapy [6,
16]. Chemotherapy is believed not to be useful in the
treatment of the disease [13]. It is difficult to obtain
a univocal opinion from published reports, and as in the
case of the extent of surgery, there is no prospective data
on the effectiveness of combined treatment in such
patients [8].
Authors generally agree in two aspects of treatment.
First, that ipsilateral axillary lymph nodes are rarely
involved in such patients and that there is no need to
remove them when they are not palpable [6-9, 14, 15].
Second, that the presence of negative resection margins is
of a crucial importance for patient survival. It has been
suggested that the results of treatment are influenced
mainly by the adequacy, not by the extent, of the surgical
procedure. The difference in the survival of patients
operated with tumor-negative and with tumor-positive
resection margins was considerable [3, 6, 13, 14, 17].
As the survival of non-epithelial malignant breast
tumor patients treated exclusively by surgery was not
evaluated in our setting we decided to perform a retro-
spective analysis of the files of such patients treated in our
center to assess the long-term results of treatment: 5-
year disease-free and overall survival, 10-year disease-
free and overall survival and median length of disease-free
and overall survival.
Material and methods
Our study comprised women treated exclusively by surgery for
breast sarcoma or malignant cystosarcoma phyllodes, between
January 1977 and December 2001 in the Clinical Department of
Surgical Oncology of the Medical University of Lodz, Poland. All
patients in case of whom resection margins were positive clini-
cally and histologically, or in case of whom adjuvant radiotherapy
and/or chemotherapy was introduced, were excluded from the
study. We also disqualified all patients with axillary lymph nodes
and/or distant metastases. Therefore, all patients in our study
group were in the local stage of the disease.
A retrospective review of the files provided complete
clinical and pathological data for 29 patients. These files were
examined for details of physical findings, treatment, results of
pathological examinations, disease recurrence and patient
survival.
Pa t i e n t  c h a r a c t e r i s t i c s
The median age at diagnosis was 53.0 years (range: 27-86 years;
mean: 54.2 years). Eleven women (38%) were of premenopausal
age (≤50) and 18 were of postmeopausal age (62%). The median
duration of symptoms (presence of tumor in the breast) was 6
months (range: 1 week – 16 years). The tumors were located in
the left breast in 11 cases (11/29; 38%) and in the right in 18
cases (18/29; 62%). The median diameter of the breast tumor
was 10 cm (range, 3-30 cm; mean, 10.4 cm). The diameter of
breast tumor exceeded 5 cm in 22/29 cases (76%). In 7 cases
the axillary lymph nodes were palpable (7/29; 24%).
Tr e a t m e n t  a n d  r e s u l t s  o f  p a t h o l o g i c
e x a m i n a t i o n
Twenty eight (97%) patients underwent mastectomy: 19 (66%) –
simple mastectomy and 9 (31%) – modified radical mastectomy
(Madden procedure). In one case (3%) wide local excision of the
tumor was performed. Diagnoses of breast sarcoma or malignant
cystosarcoma phyllodes were confirmed postoperatively in the
course of the histological analysis. The distribution of the
histological types of malignancies is presented in Table I. In all
cases the surgical procedure was radical, i.e. no residual
microscopic disease was found histologically at the excision
margins. Metastases in the axillary lymph nodes were not
discerned in the post-lymphadenectomy specimens.
Table I. Histological types of malignancy in 29 patients with non-
epithelial malignant breast tumors
Histologic type of malignancy Number Number 
of patients of deaths
Cystosarcoma phyllodes 14 3
Sarcoma stromale 6 3
Fibrosarcoma 5 0
Haemangiosarcoma 2 1
Liposarcoma 2 1
Total 29 8
S t a t i s t i c s
Mean and median disease-free survival times were calculated by
the product-limit estimate method. Disease-free and overall
survival probabilities were calculated according to the Kaplan-
Meier method for the estimation of survival functions. To
compare the survival distributions the log-rank test was applied.
P-value<0.05 was considered significant. All analyses were
performed with Statistica software.
Results
Re c u r r e n c e  o f  d i s e a s e ,  d e a t h s
Five of the 29 patients (17%) developed local recurrence.
Two patients (7%) developed recurrence in the ipsilateral
axillary lymph nodes. Nine patients (31%) developed
symptoms of distant metastases, predominantly pulmo-
nary (7/9 cases). Altogether, relapse of the disease was
observed in 11 patients (38%). Ten of these 11 patients
had tumors bigger than 5 cm. Eight patients died during
follow-up (28%). All patients who died had tumors bigger
than 5 cm.
D i s e a s e - f r e e  s u r v i v a l
The 5-year disease-free survival probability for the entire
group was 0.55. The 10-year disease-free survival
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probability was 0.44 (Figure 1). The median disease-free
survival was 119.0 months (mean: 117.2 months).
The probability of disease-free survival for patients
with tumors not exceeding 5 cm was 0.75 at 5 years and
0.75 at 10 years (Figure 3). The mean disease-free survival
for these patients was 133.5 months. It was impossible to
calculate a median value of disease-free survival for these
patients.
The 5-year disease-free survival probability for
patients with tumors exceeding 5 cm was 0.48. The 10-
year disease-free survival probability in this subgroup was
0.36 (Figure 3). The median disease-free survival was
36.0 months (mean: 99.9 months).
The difference between disease-free survival curves
for tumor sizes was statistically not significant (log rank
test statistic 2.09; df=1; p=0.15)
The probability of disease-free survival for patients
with malignant cystosarcoma phyllodes was 0.71 at 5 years
and 0.36 at 10 years (Figure 5). The mean disease-free
survival for these patients was 123.5 months. The median
disease-free survival was 119.0 months.
The 5-year disease-free survival probability for
patients with breast sarcoma was 0.43. The 10-year
disease-free survival probability in this subgroup was also
0.43 (Figure 5). The mean disease-free survival for these
patients was 90.1 months. The median disease-free
survival was 36.0 months.
The difference between disease-free survival curves
(malignant cystosarcoma phyllodes vs. breast sarcoma)
was statistically not significant (log rank test statistic 0.67;
df=1; p=0.41)
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Figure 1. Disease-free survival of patients with non-epithelial malignant breast tumors
Figure 2. Overall survival of patients with non-epithelial malignant breast tumors
O v e r a l l  s u r v i v a l
The 5-year overall survival probability was 0.69. The 10-
year overall survival probability was 0.61 (Figure 2). The
median overall survival was 129.0 months (mean: 137.3
months).
For patients with tumors not exceeding 5 cm the 5-
year overall survival probability was 1.00 and the 10-year
overall survival probability was 1.00 (Figure 4). Survival
estimates could not be computed for these patients since
all observations were censored.
For patients with tumors exceeding 5 cm the 5-year
overall survival probability was 0.60 and the 10-year
overall survival probability was 0.52 (Figure 4); the
median overall survival was 129.0 months (mean: 118.7
months).
The difference between overall survival curves for
tumor sizes was statistically not significant (log rank test
statistic 2.54; df=1; p=0.11)
For patients with malignant cystosarcoma phyllodes
the 5-year overall survival probability was 0.91, the 10-
year overall survival probability was 0.68 (Figure 6); the
median overall survival was 142.0 months (mean: 129.0
months).
For patients with breast sarcoma the 5-year overall
survival probability was 0.54; the 10-year overall survival
probability was 0.54 (Figure 6). The mean overall survival
for these patients was 113.5 months. It was impossible to
calculate a median value of overall survival for these
patients.
The difference between overall survival curves
(malignant cystosarcoma phyllodes vs. breast sarcoma)
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Figure 3. Disease-free survival of patients with non-epithelial malignant breast tumors in relation 
to tumor size
Figure 4. Overall survival of patients with non-epithelial malignant breast tumors in relation to tumor size
was statistically not significant (log rank test statistic 0.28;
df=1; p=0.59).
Discussion
The results of our study indicate that 5-year disease-free
survival probability is very low. The calculated value is
close to 0.5, despite achieving histologically confirmed
tumor-negative resection margins during surgery. The
probability of 5-year overall survival is somewhat better
and close to 0.7. During the next five years after surgery
(from the 6th to the 10th year of follow-up) both
probabilities drop slightly by about 0.1 each. This is
caused by the fact, that the majority of relapses and
deaths took place during the first two years of follow-up
(Figure 1 and 2).
Disease-free survival probabilities, as well as overall
survival probabilities calculated for our patients, are
within the ranges of values reported in medical literature
[4, 6, 7, 9, 12, 16, 19]. However, it should be stressed that
any comparison of treatment results of non-epithelial
malignant breast tumor patients is very difficult. The
studied groups of patients differ significantly from each
other in the distribution of histologic types of malignan-
cies, the grade and size of the primary tumors at
presentation, the number of studied patients and the
percentage of patients operated with positive resection
margins. Moreover, many authors mix the treatment
results of patients treated solely by surgery with those
treated also with postoperative adjuvant therapy, creating
therapeutically non-homogenous study group. Therefore
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Figure 5. Disease-free survival of patients: malignant cystosarcoma phyllodes vs. breast sarcoma
Figure 6. Overall survival of patients: malignant cystosarcoma phyllodes vs. breast sarcoma
comparisons of treatment results should be performed
with due caution.
Our observations concerning the time distributions
of relapses and deaths are similar to published data. No
matter what treatment option is used, the shapes of the
survival curves of non-epithelial malignant breast tumor
patients are similar [3, 8, 16]. The majority of relapses
are observed during the first two and five years of follow-
up. After five years they are rare or are not encountered
at all [5, 8, 9, 16, 17].
In a majority of our patients (10/11; 91%) in whom
relapse was observed, the size of the primary tumor
exceeded 5 cm. Similarly, all patients who had died due to
disease progression during follow-up had presented with
primary tumors exceeding 5 cm. Although the disease-
free and overall survival curves are apparently different in
patients with tumors larger and smaller than 5 cm, the
differences do not reach the significance level. The
phenomenon was probably caused by the small numbers
of patients in the two compared subgroups.
Patients from our study group had huge breast
tumors (mean size: 10.4 cm; median size: 10 cm). The
majority of the primary tumors in the studied group
exceeded 5 cm (22/29; 76%). The biggest tumor was 30
cm in diameter. It was probably related to the long
duration of symptoms before presentation (median: 6
months) in the studied group. It also means that the
majority of our patients were at a high risk of recurrence.
We had no doubts concerning the extent of surgery. The
size of the primary tumors was such, that in order to
achieve wide (2-3 cm) tumor-negative resection margins
around the primary tumor we had to perform mastecto-
mies in 28 out of 29 of our patients (97%). Only one
patient underwent a limited surgical procedure. This
woman did not develop recurrence. Axillary lympha-
denectomy was performed in the case of enlarged lymph
nodes and when we suspected metastases, or in those
cases where the lymphadenectomy was necessary to
achieve proper surgical margins around the primary
tumor. We cannot discuss the necessity of axillary lymph
node dissection as patients with metastases in the axillary
lymph nodes were considered to have disseminated
disease at presentation, and were excluded from the study
group.
Our observations are in concordance with other
reports – that the larger the primary tumor, the higher is
the risk of relapse [8, 13, 18] and that the incidence of
recurrence is increased in patients with tumors exceeding
5 cm [8, 13, 18]. However, we believe that our study is
unique as the mean and median sizes of tumors are
unusually large. There are few reports in modern medical
literature concerning such huge non-epithelial malignant
breast tumors [19].
A comparison of the survival of patients with
malignant cystosarcoma phyllodes and with breast
sarcoma did not reveal significant differences. However,
breast sarcoma patients presented with failures earlier
during the course of the disease. The same observation is
also reported in literature [3].
In the studied group no adjuvant radiotherapy was
used. As the role of postoperative radiotherapy has not
been confirmed, we cannot consider our therapeutical
decisions as mistakes. However, one may find more and
more suggestions that adjuvant therapy may be beneficial
in such patients [8, 17] especially in case of large tumors
[8]. Therefore we believe that adjuvant radiotherapy
should be considered in patients who present with
tumours exceeding 5 cm. We also stress the necessity of
staging a multicenter prospective study on the treatment
of patients with non-epithelial malignant breast tumors.
Conclusions
The probability of disease relapse in patients with non-
epithelial malignant breast tumor treated surgically is
high in patients with tumors exceeding 5 cm.
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